let-7 inhibition of ES cell reprogramming

No Pathway Network information available for let-7 inhibition of ES cell reprogramming

Pathways in the let-7 inhibition of ES cell reprogramming SuperPath

#	Name	Source	Genes
1	let-7 inhibition of ES cell reprogramming	WikiPathways	EGR1 KLF4 MIRLET7A1 MIRLET7A2 MIRLET7C MIRLET7D MIRLET7E MIRLET7F1 MIRLET7F2 MIRLET7G MIRLET7I MYC POU5F1 SOX2 TRIM71 (see all 15) (see less)
2	Metastatic brain tumor	WikiPathways	CDC42 CDK6 E2F3 MIR29C MIRLET7A1 MIRLET7C MIRLET7D MIRLET7E MIRLET7F1 MIRLET7G MYC PIK3R1 TP53 (see all 13) (see less)

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	2
2	MIRLET7G	MicroRNA Let-7g	RNA Gene	2
3	MIRLET7E	MicroRNA Let-7e	RNA Gene	2
4	MIRLET7D	MicroRNA Let-7d	RNA Gene	2
5	MIRLET7C	MicroRNA Let-7c	RNA Gene	2
6	MIRLET7F1	MicroRNA Let-7f-1	RNA Gene	2
7	MIRLET7A1	MicroRNA Let-7a-1	RNA Gene	2
8	KLF4	KLF Transcription Factor 4	Protein Coding	1
9	SOX2	SRY-Box Transcription Factor 2	Protein Coding	1
10	POU5F1	POU Class 5 Homeobox 1	Protein Coding	1
11	MIRLET7I	MicroRNA Let-7i	RNA Gene	1
12	EGR1	Early Growth Response 1	Protein Coding	1
13	TRIM71	Tripartite Motif Containing 71	Protein Coding	1
14	MIRLET7F2	MicroRNA Let-7f-2	RNA Gene	1
15	MIRLET7A2	MicroRNA Let-7a-2	RNA Gene	1
16	PIK3R1	Phosphoinositide-3-Kinase Regulatory Subunit 1	Protein Coding	1
17	CDC42	Cell Division Cycle 42	Protein Coding	1
18	TP53	Tumor Protein P53	Protein Coding	1
19	MIR29C	MicroRNA 29c	RNA Gene	1
20	E2F3	E2F Transcription Factor 3	Protein Coding	1
21	CDK6	Cyclin Dependent Kinase 6	Protein Coding	1

Disorders associated with let-7 inhibition of ES cell reprogramming SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Microcephaly 12, primary, autosomal recessive	Enrichment	CDK6	3.02
2	Short syndrome	Enrichment	PIK3R1	3.02
3	Bone marrow failure syndrome 5	Enrichment	TP53	3.02
4	Papilloma of choroid plexus	Enrichment	TP53	3.02
5	Basal cell carcinoma 7	Enrichment	TP53	3.02
6	Anaplastic thyroid carcinoma	Enrichment	TP53	3.02
7	Immunodeficiency 36 with lymphoproliferation	Enrichment	PIK3R1	3.02
8	Agammaglobulinemia 7, autosomal recessive	Enrichment	PIK3R1	3.02
9	Ductal carcinoma in situ	Enrichment	TP53	3.02
10	Takenouchi-kosaki syndrome	Enrichment	CDC42	3.02
11	Thyroid gland undifferentiated carcinoma	Enrichment	TP53	3.02
12	Small-cell carcinoma of the ovary of hypercalcemic type	Enrichment	TP53	3.02
13	Diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype	Enrichment	TP53	3.02
14	Choroid plexus cancer	Enrichment	TP53	3.02
15	Nocarh syndrome	Enrichment	CDC42	3.02
16	Pleomorphic xanthoastrocytoma	Enrichment	TP53	3.02
17	Hydrocephalus, congenital, 4	Enrichment	TRIM71	2.96
18	Burkitt lymphoma	Enrichment	MYC	2.72
19	Adrenocortical carcinoma, hereditary	Enrichment	TP53	2.72
20	Cervical cancer	Enrichment	TP53	2.72
21	Lymphoma, hodgkin, classic	Enrichment	TP53	2.72
22	Congenital fibrosarcoma	Enrichment	TP53	2.72
23	Li-fraumeni syndrome 1	Enrichment	TP53	2.72
24	Sarcoma	Enrichment	TP53	2.72
25	Cervix carcinoma	Enrichment	TP53	2.72
26	Immune system disease	Enrichment	CDC42	2.72
27	Hodgkin's lymphoma	Enrichment	TP53	2.72
28	Pleomorphic rhabdomyosarcoma	Enrichment	TP53	2.72
29	Osteogenic sarcoma	Enrichment	TP53	2.54
30	Nasopharyngeal carcinoma	Enrichment	TP53	2.54
31	Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi	Enrichment	PIK3R1	2.54
32	Immunodeficiency 14a with lymphoproliferation, autosomal dominant	Enrichment	PIK3R1	2.54
33	High-grade b-cell lymphoma double-hit/triple-hit	Enrichment	MYC	2.54
34	Atypical teratoid rhabdoid tumor	Enrichment	TP53	2.54
35	Anaplastic astrocytoma	Enrichment	TP53	2.54
36	Immunodeficiency 14	Enrichment	PIK3R1	2.54
37	Squamous cell carcinoma	Enrichment	TP53	2.54
38	Adenocarcinoma	Enrichment	TP53	2.54
39	Bone osteosarcoma	Enrichment	TP53	2.54
40	Colorectal cancer	Enrichment	PIK3R1, TP53	2.52
41	Small cell cancer of the lung	Enrichment	TP53	2.42
42	Thyroid cancer, nonmedullary, 1	Enrichment	TP53	2.42
43	Lung sarcomatoid carcinoma	Enrichment	TP53	2.42
44	Embryonal rhabdomyosarcoma	Enrichment	TP53	2.42
45	Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia	Enrichment	CDC42	2.42
46	Microphthalmia, syndromic 3	Enrichment	SOX2	2.35
47	Hydrocephalus, congenital, 2, with or without brain or eye anomalies	Enrichment	TRIM71	2.35
48	Rhabdomyosarcoma 2	Enrichment	TP53	2.32
49	Lymphoma	Enrichment	TP53	2.32
50	Acute megakaryocytic leukemia	Enrichment	TP53	2.32
51	Li-fraumeni syndrome	Enrichment	TP53	2.24
52	Adrenocortical carcinoma	Enrichment	TP53	2.24
53	Breast adenocarcinoma	Enrichment	TP53	2.24
54	Esophageal cancer	Enrichment	TP53	2.17
55	Squamous cell carcinoma, head and neck	Enrichment	TP53	2.17
56	Essential thrombocythemia	Enrichment	TP53	2.17
57	Gallbladder cancer	Enrichment	TP53	2.17
58	Overgrowth syndrome	Enrichment	PIK3R1	2.17
59	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	Enrichment	TP53	2.17
60	Glioma susceptibility 1	Enrichment	TP53	2.12
61	Lymphoma, non-hodgkin, familial	Enrichment	TP53	2.12
62	Congenital hydrocephalus	Enrichment	TRIM71	2.11
63	Adult hepatocellular carcinoma	Enrichment	TP53	2.07
64	Primary hyperaldosteronism	Enrichment	TP53	2.07
65	Leukemia, chronic lymphocytic	Enrichment	TP53	2.02
66	Familial colorectal cancer	Enrichment	TP53	2.02
67	Autosomal non-syndromic agammaglobulinemia	Enrichment	PIK3R1	2.02
68	Myelodysplastic syndrome	Enrichment	TP53	1.98
69	Lip and oral cavity carcinoma	Enrichment	TP53	1.94
70	Nanophthalmos	Enrichment	SOX2	1.92
71	Septooptic dysplasia	Enrichment	SOX2	1.88
72	Lung cancer susceptibility 3	Enrichment	TP53	1.87
73	Rhabdomyosarcoma	Enrichment	TP53	1.82
74	Gliosarcoma	Enrichment	TP53	1.82
75	Giant cell glioblastoma	Enrichment	TP53	1.79
76	Diffuse large b-cell lymphoma	Enrichment	TP53	1.74
77	Hepatoblastoma	Enrichment	TP53	1.70
78	Hepatocellular carcinoma	Enrichment	TP53	1.68
79	Diamond-blackfan anemia 1	Enrichment	TP53	1.66
80	Precursor t-cell acute lymphoblastic leukemia	Enrichment	MYC	1.66
81	Macs syndrome	Enrichment	SOX2	1.66
82	Pancreatic cancer	Enrichment	TP53	1.63
83	Microphthalmia	Enrichment	SOX2	1.62
84	Bladder cancer	Enrichment	TP53	1.56
85	Prostate cancer	Enrichment	TP53	1.56
86	Primary autosomal recessive microcephaly	Enrichment	CDK6	1.52
87	Diamond-blackfan anemia	Enrichment	TP53	1.47
88	Leukemia, acute myeloid	Enrichment	TP53	1.42
89	Gastric cancer	Enrichment	TP53	1.39
90	Hereditary breast carcinoma	Enrichment	TP53	1.38
91	Hereditary breast ovarian cancer syndrome	Enrichment	TP53	1.29
92	Myeloma, multiple	Enrichment	TP53	1.28
93	Breast cancer	Enrichment	TP53	1.16
94	Ovarian cancer	Enrichment	TP53	1.03
95	Inherited cancer-predisposing syndrome	Enrichment	TP53	0.92

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

let-7 inhibition of ES cell reprogramming

Pathway Network for let-7 inhibition of ES cell reprogramming

Member Pathways for let-7 inhibition of ES cell reprogramming

Pathways in the let-7 inhibition of ES cell reprogramming SuperPath

Associated Genes for let-7 inhibition of ES cell reprogramming

Associated Disorders for let-7 inhibition of ES cell reprogramming

Disorders associated with let-7 inhibition of ES cell reprogramming SuperPath

STRING Interaction Network for let-7 inhibition of ES cell reprogramming

Sources for let-7 inhibition of ES cell reprogramming